Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-17 21:31:33 ET · period of report 2026-09-15 · accession 0001763494-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:31 | 2026-09-15+ | TVTX | Dube Eric M | CEO, Dir | M - OptEx | $23.34 | +400.0K | 541.4K | +283% | +$9.34M |
| DMT | 2026-09-17 21:31 | 2026-09-15+ | TVTX | Dube Eric M | CEO, Dir | S - Sale+OE | $63.48 | -400.0K | 432.9K | -48% | -$25.39M |
| DMT | 2026-09-17 21:31 | 2026-09-15+ | TVTX | Dube Eric M | CEO, Dir | M - OptEx | $0.00 | -400.0K | 0 | -100% | $0 |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 95,666 | $23.34 | 528,552 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-15 | S | D | 63,498 | $61.99 | 465,054 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F2) The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2026-09-15 | S | D | 28,796 | $62.66 | 436,258 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F3) The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 3,102 | $63.64 | 433,156 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F4) The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 270 | $65.31 | 432,886 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| 6 | Common | Common Stock | 2026-09-16 | M | A | 195,841 | $23.34 | 628,727 | D | — | — | |
| 7 | Common | Common Stock | 2026-09-16 | S | D | 99,716 | $63.26 | 529,011 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F5) The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 8 | Common | Common Stock | 2026-09-16 | S | D | 96,125 | $63.64 | 432,886 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F6) The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 9 | Common | Common Stock | 2026-09-17 | M | A | 108,493 | $23.34 | 541,379 | D | — | — | |
| 10 | Common | Common Stock | 2026-09-17 | S | D | 101,691 | $64.59 | 439,688 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F7) The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 11 | Common | Common Stock | 2026-09-17 | S | D | 6,802 | $64.95 | 432,886 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F8) The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 12 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 95,666 | $0.00 | 304,334 | D | $23.34 · — to 2029-01-04 | 95,666 Common Stock | (F9) The stock option is fully vested and exercisable. |
| 13 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 195,841 | $0.00 | 108,493 | D | $23.34 · — to 2029-01-04 | 195,841 Common Stock | (F9) The stock option is fully vested and exercisable. |
| 14 | Derivative | Employee stock option (right to buy) | 2026-09-17 | M | D | 108,493 | $0.00 | 0 | D | $23.34 · — to 2029-01-04 | 108,493 Common Stock | (F9) The stock option is fully vested and exercisable. |